FDA Grants Fast Track Designation to Nuvectis Pharma’s NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

December 1, 2022

https://www.globenewswire.com/news-release/2022/12/01/2565889/0/en/FDA-Grants-Fast-Track-Designation-to-Nuvectis-Pharma-s-NXP800-for-the-Treatment-of-Platinum-Resistant-ARID1A-Mutated-Ovarian-Carcinoma.html

Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ:NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma.

Read more at globenewswire.com

Related news for (NVCT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.